Author Archives: Antonio Pesqueira

Critical Success Factors to Imprinting Innovation into Segmentation and Targeting – Pharma Commercial Excellence perspectives

In the Pharmaceutical Industry the customer value proposition traditionally is a complex path to understand, being constantly changing with different assumptions, where unprepared business models can struggle to identify not only those changes as well future patterns and gain effective competitive advantage in a challenging industry. The traditional Pharma Commercial Share-of-Voice driven approach, was mainly focused […]

Rethinking Pharmaceutical Competitive Intelligence in 2016

Most of the pharmaceutical companies continues to face crescent competition in the operating markets from different sources. Some of the solutions to overcome the current difficulties and barriers, may be a constant search of new R&D methods and new operations mechanisms in order to obtain economic scale and gain new commercial capabilities that can drive or improve effectiveness from R&D investments.

What trends are reshaping the pharma Landscape in 2016?

Not only the patients or physicians are increasing the mobile and digital usage on their needs, we are also understanding that more than ever the Health Authorities, regulatory agencies and payers are requesting more digital services and using more digital products through online and mobile usage to address traditional and new requirements. Combined with this growing usage and demanding, pharma companies have amazing opportunities to provide content and information essential to obtain products approvals, increase the success rates for reimbursement and drive more awareness around products efficacy, safety and clinical trials results.

Understanding Centricity Blog

2016: Global Top 12 Pharma and Biotech companies by Revenue in 2015

The global Pharmaceutical market has reached an incredible milestone of global sales revenue in 2015 of almost €1.2 trillion, with strong forecasts to increase to €1.6 trillion by 2018.

Only the 12 largest companies in the Pharmaceutical & Biotechnology landscape achieved €325 billion of revenue only from the Pharmaceutical Divisions (e.g. J&J Business Units divisions are: Pharma, Consumer and Medical Devices), reflecting already a market share of 31.8%.

Understanding Centricity Blog

Top 12 Pharmaceutical & BioTechnology Companies in 2016 – Ranking by Revenue and Market Potential index

Top 12 Pharmaceutical & BioTechnology in 2016 – Ranking
The global Pharmaceutical market has reached an incredible milestone of global sales revenue in 2015 of almost €1.2 trillion, with strong forecasts to increase to €1.6 trillion by 2018.
Only the 12 largest companies in the Pharmaceutical & Biotechnology landscape achieved the impressive milestone of €325 billion revenue only from the Pharmaceutical Divisions (e.g. J&J Business Units divisions are: Pharma, Consumer and Medical Devices), reflecting already a market share of 31.8%.
The Pharma&BioTech market globally shows high levels of consolidation and maturity, where in the last year the activities around M&A were intense and the concentration in terms of market share was quite expressive.
Looking at the primary location of half of the 12 companies, United States have a strong representation of 6 companies, followed by different European countries (Switzerland [2], U.K. [2] and then France [1] and Germany [1]).

Understanding Centricity Antonio Pesqueira

Essential components of a Multichannel and Digital strategic planning in Pharma: Content and Integration are key (Part V)

Some of the biggest challenges in Multichannel Marketing (MCM) programs, have to do with the delivered content itself and how the responsible departments plans the master data design models to support the entire program and how systems, data and platforms integration are architected to deliver results and sustainable outcomes.

Understanding Centricity Antonio Pesqueira

Making the Multichannel Marketing (MCM) Strategy Relevant in Life Sciences: 2016 perspectives (Part IV)

Online and digital are no longer meaningless concepts to most of the patients, where a large percentage of them across most of the EU countries are using already apps to compare drug prices, learn more about diseases, search for new physicians (2nd opinions) or treatments. In this growing environment are the current pharma companies being able and flexible to support the necessary knowledge development on their products and with that leverage not only the patient’s awareness around the product, but as well the doctor’s knowledge and engagement? How important is the word-of-mouth for Pharma in 2016?